GridAI Technologies (GRDX) Receivables - Net (2015 - 2025)

GridAI Technologies' (GRDX) quarterly Receivables - Net came in at $29974.0 in Q4 2025, down 20.05% on a QoQ basis from $37490.0 in Q3 2025.

GridAI Technologies (GRDX) Receivables - Net (2015 - 2025) Analysis & Trends

GridAI Technologies (GRDX) has 10 years of Receivables - Net data on file, last reported at $29974.0 in Q4 2025.

Quarterly Receivables - Net changed N/A year-over-year to $29974.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29974.0 (changed N/A YoY) and the FY2025 annual result came in at $29974.0, changed N/A from the prior year.
Receivables - Net eased to $29974.0 in Q4 2025, from $37490.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $501660.0 in Q1 2021 to a low of $20000.0 in Q1 2023.
A 4-year average of $121575.8 and a median of $53959.5 in 2022 frame the typical range for Receivables - Net.
Annual changes were most pronounced in 2022 — Receivables - Net slumped 94.41% — and 2023, when it retreated 28.71%.
Tracing GRDX's Receivables - Net over 4 years: stood at $501660.0 in 2021, then plunged by 81.46% to $93014.0 in 2022, then tumbled by 78.5% to $20000.0 in 2023, then soared by 49.87% to $29974.0 in 2025.
The last three Receivables - Net figures came in at $29974.0 (Q4 2025), $37490.0 (Q3 2025), and $20000.0 (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	GridAI Technologies	6.09 Mn	6.09 Mn	-

Download Data